Getting your player ready...
TRENTON, N.J. — Federal regulators have warned Johnson & Johnson that it could face fines and other sanctions for selling faulty insulin pumps and delaying disclosures of serious injuries to diabetics who were using its OneTouch Ping and 2020 pumps.
The Food and Drug Administration ordered J&J’s Animas Corp. unit to explain why it kept selling pumps known to fail and also to submit a plan to rectify its failure to promptly report cases.
